Abstract:Supplemental Figures S1-S7. Supplemental Figure S1: The structures of GSK2126458 and PKI-587; Supplemental Figure S2: GSK2126458 and PKI-587 inhibit NPC proliferation by blocking PI3K/mTOR signaling; Supplemental Figure S3: GSK2126458 and PKI-587 inhibit migration and invasion of NPC cells; Supplemental Figure S4: Targeting the PI3K/mTOR pathway with GSK2156458 or PKI-587 increases the radiosensitivity of NPC cells; Supplemental Figure S5: Radiosensitization induced by the dual PI3K/mTOR inhibitors is accompanied by persistence of y-H2AX foci; Supplemental Figure S6: The combination of IR and dual PI3K/mTOR inhibitors induces cell cycle arrest in NPC cells; Supplemental Figure S7: Combination of dual inhibition of PI3K/mTOR and radiation therapy is an effective treatment for NPC in vivo.

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplementary Figures 1-3 from OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

Supplementary Figure 2 from Dual Inhibition of PI3K and Mtor Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Supplementary Figure 1 from Dual Inhibition of PI3K and Mtor Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Supplementary Figure S2 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Legend for Supplementary Figures from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma

Supplementary Figure S6 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Supplementary Figure 5 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Figure 4 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Figure 6 from Cooperation Between <i>pik3ca</i> and P53 Mutations in Mouse Mammary Tumor Formation

Supplementary Figures 1-4 from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Supplemental Figure 2 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

Supplementary Figure 1 from Cooperation Between Pik3ca and P53 Mutations in Mouse Mammary Tumor Formation

Supplementary Figure 3 from Cooperation Between Pik3ca and P53 Mutations in Mouse Mammary Tumor Formation

Supplementary Figures 1-3 from Genetic Background Controls Tumor Development in <i>Pten</i>-Deficient Mice

Supplementary Figure 7 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

Supplemental Figures S1-S7 from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma

Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth